Drug intelligence / Profile preview

ICM-322

Development stage: Preclinical
Lead developer: ICM
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Ophthalmic

Overview

ICM-322 is an adeno-associated virus (AAV)-based gene therapy under development by ICM, a South Korean biotechnology company. The therapy is designed to treat degenerative and inherited retinal diseases by delivering therapeutic genetic material to retinal cells. Utilizing ICM's proprietary AAV gene therapy platform, ICM-322 aims to address the underlying causes of vision loss in these conditions. As of early 2024, the program is in the preclinical stage of development, and the specific molecular or genetic target has not been publicly disclosed.

Other names: Nkx3.2-based gene therapyNkx-3.2-based gene therapyNkx 3.2-based gene therapy

Beyond the preview

Go deeper on ICM-322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICM-322.

Explore the full profile